Portfolio overlap

IBB / TMED

Overlap	Shared positions
19.49%	48

iShares Biotechnology ETF

Report dates 06/30/2026 | 99.88% NAV

Overlap / IBB 28.85%

T. Rowe Price Health Care ETF

Report dates 06/30/2026 | 99.19% NAV

Overlap / TMED 29.04%

Largest shared positions

Security	IBB	TMED	Overlap
Gilead Sciences, Inc.	6.84%	4.44%	4.44%
Alnylam Pharmaceuticals, Inc.	3.12%	2.60%	2.60%
Biogen, Inc.	2.47%	1.55%	1.55%

Weights are percentages of each fund's net assets. Shared weight is the sum of the smallest weight per matched common-stock class. Unmatched positions are excluded without renormalizing the weights.

History





5 matched portfolio dates from 06/30/2025 to 06/30/2026. Both filings use the same portfolio date. The minimum matched share of net assets is 98.93%. The filing dates are 56–286 days after the portfolio dates. This is filing lag. The archive does not establish an exact intraday release time.

Largest changes

03/31/2026 / 06/30/2026 -1.99 pp

Security	Overlap 03/31/2026	Overlap 06/30/2026	Change (pp)
Ascendis Pharma A/S	0.00%	1.29%	+1.29
Regeneron Pharmaceuticals, Inc.	1.02%	0.00%	-1.02
Ascendis Pharma A/S	0.96%	0.00%	-0.96
Alnylam Pharmaceuticals, Inc.	2.06%	2.60%	+0.54
Alkermes plc	0.53%	0.00%	-0.53
All other shared classes			-1.31

Sources and methodology

Weights are percentages of each fund's net assets. Shared weight is the sum of the smallest weight per matched common-stock class. Unmatched positions are excluded without renormalizing the weights.

nport-common-equity-v1

Report dates	Weight (%)	Classes	IBB · SEC	TMED · SEC
06/30/2026	19.49%	48	0002071691-26-019768	0001099263-26-009630
03/31/2026	21.48%	56	0002071691-26-012466	0001099263-26-006632
12/31/2025	15.80%	47	0002071691-26-004248	0001099263-26-002583
09/30/2025	15.40%	39	0002071691-26-015779	0001099263-25-003676
06/30/2025	16.71%	47	0001752724-25-210361	0001795351-25-000523